Denisse Castro-Eguiluz, PhD


Treatment of Locally Advanced Cervical Cancer With Kidney Failure and Comorbidities

In this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.

Donald Barry Boyd, MD, MS


Avelumab Maintenance for Urothelial Carcinoma: Real-World Evidence

Daniel Petrylak, MD and Donald Barry Boyd, MD, MS, examine real-world data presented in the recent publication, “Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.”

Diogo Assed Bastos, MD


Use of Immunotherapy in Patients With Cancer During the COVID-19 Pandemic

This article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.

Pamela B. Allen, MD


Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer

ABSTRACT Adolescents and young adults (AYAs) with cancer constitute approximately 70,000 patients diagnosed each year. Survival rates for AYAs with cancer have increased steadily in recent decades due to improvements in therapeutic regimens and early detection. Given the large and growing number of AYA cancer survivors, additional research is needed on the immediate and long-term psychosocial support required for this population including family planning and fertility. Fertility and fertility preservation in female AYAs, in particular, is historically understudied and has psychologically relevant ramifications distinct from male AYAs. Decision science can contribute to this area of oncological care and has implications for clinical encounters and research concerning female AYA patients with cancer. Patient-centered care and shared decision-making that integrates recent research regarding fertility preservation in the context of cancer treatment can improve outcomes for AYA cancer survivors.

Joshua K. Sabari, MD


Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Yusuf Z. Şener, MD


Metastatic Renal Cell Carcinoma With Sarcomatoid Features

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.

Lindsay Fischer


Axi-Cel Improves Survival Vs SOC in Relapsed/Refractory LBCL

Axicabtagene ciloleucel produces a higher median overall survival vs high-dose therapy plus autologous stem cell transplant among patients with relapsed or refractory large B-cell lymphoma in the phase 3 ZUMA-7 trial.

Daniel H. Ahn, DO


Circulating Tumor DNA and MRD Assessment in Colorectal Cancer

The expert panel offers closing thoughts on MRD assessment and how ctDNA has been incorporated into clinical practice in the treatment of colorectal cancer.

Ana Beatriz Fernández Román, PharmG


Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data

Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.

Preet M. Chaudhary, MD, PhD


Treatment Experience for a Patient With GVHD

A patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.

Omar Nadeem, MD


Managing AEs Associated With Bispecifics in RRMM

Closing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.

Michael Lin-Brande, MD


Primary Focal Therapy for Localized Prostate Cancer: A Review of the Literature

Focal therapy for prostate cancer could balance undertreatment and overtreatment of localized prostate cancer for highly selected patients. Long-term oncologic outcomes are not yet available for any modality. Patients should be informed regarding currently available outcomes, the necessity of adherence to a stringent follow-up protocol, and the possible need for additional targeted therapy or future radical treatment in case of recurrence.

Bhumika Patel, MD


Tagraxofusp in BPDCN: Practical Advice and Future Directions in Care

After sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.

Roger Li, MD


Roger Li, MD, Talks Future Analyses of CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC

Roger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

Inga Lennes, MD, MBA, MPH


Medical World News® After Hours: Thoracic Medical Oncologist Inga Lennes, MD, MBA, MPH, on Healthy Eating

During an After Hours segment of Medical World News®, Inga Lennes, MD, MBA, MPH, spoke about her passion for healthy cooking and how it helps her unwind after a busy week of treating patients.

Sandra P. D’Angelo, MD


Novel Therapies May Lead to More Treatment Options in Sarcoma Subtypes

CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.

Barry Hammer, PA-C


Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma

Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.

Abhishek Mangaonkar, MBBS


Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical Progression

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.

Martha Ann Raymond, MA


Martha Ann Raymond, MA, on What Providers Should Do to Enhance Clinical Trial Participation in the COVID-19 Era

The founding executive director of the GI Cancers Alliance discussed important takeaways from a study of patient perspectives of clinical trial participation during the COVID-19 pandemic.

Sagar Lonial, MD, FACP


Patient Case Introduction: 66-year-old Male Diagnosed with R/R MM

Subject matter experts share strategies for determining treatment selection and duration for patients with transplant-ineligible NDMM.

Catherine A. Shu, MD


Catherine A. Shu, MD, Reviews Findings of Cohort A of the Phase 1 CHRYSALIS-2 Trial in Pretreated EGFR+ NSCLC

Catherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.

Paul A. Moore, PhD


Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.